SG11202005526WA - Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis - Google Patents

Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Info

Publication number
SG11202005526WA
SG11202005526WA SG11202005526WA SG11202005526WA SG11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA
Authority
SG
Singapore
Prior art keywords
formulations
prevention
treatment
atopic dermatitis
peptide immunogens
Prior art date
Application number
SG11202005526WA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of SG11202005526WA publication Critical patent/SG11202005526WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
SG11202005526WA 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis SG11202005526WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597130P 2017-12-11 2017-12-11
PCT/US2018/065025 WO2019118512A2 (en) 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Publications (1)

Publication Number Publication Date
SG11202005526WA true SG11202005526WA (en) 2020-07-29

Family

ID=66820956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005526WA SG11202005526WA (en) 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Country Status (12)

Country Link
US (1) US20210079054A1 (es)
EP (1) EP3724218A2 (es)
JP (1) JP7250032B2 (es)
KR (1) KR20210009296A (es)
CN (1) CN111448208B (es)
AU (1) AU2018383708B2 (es)
BR (1) BR112020011308A2 (es)
CA (1) CA3085318A1 (es)
MX (1) MX2020006105A (es)
SG (1) SG11202005526WA (es)
TW (1) TWI741241B (es)
WO (1) WO2019118512A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
EP4021499A1 (en) * 2019-08-29 2022-07-06 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
AU2021383841A1 (en) * 2020-11-23 2023-06-22 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
US20180267024A1 (en) * 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
JP6987744B2 (ja) * 2015-09-08 2022-01-05 ウニヴェルズィテート チューリッヒ 虫刺され過敏症の治療
NZ747512A (en) * 2016-04-27 2023-05-26 Benchmark Animal Health Ltd Treatment of canine atopic dermatitis

Also Published As

Publication number Publication date
TW201927813A (zh) 2019-07-16
CN111448208A (zh) 2020-07-24
RU2020122924A (ru) 2022-01-14
AU2018383708A1 (en) 2020-07-16
BR112020011308A2 (pt) 2020-11-17
CN111448208B (zh) 2024-02-27
US20210079054A1 (en) 2021-03-18
CA3085318A1 (en) 2019-06-20
JP7250032B2 (ja) 2023-03-31
WO2019118512A3 (en) 2020-04-09
EP3724218A2 (en) 2020-10-21
MX2020006105A (es) 2020-11-09
JP2021510169A (ja) 2021-04-15
TWI741241B (zh) 2021-10-01
WO2019118512A2 (en) 2019-06-20
KR20210009296A (ko) 2021-01-26
AU2018383708B2 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
IL268406A (en) Preparations and methods for treating hemoglobin diseases
SG11202005526WA (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
IL290150A (en) Compounds and methods for treating chronic pain
SG10201402819WA (en) Composition for prevention and treatment of joint pain and the method of preparation thereof
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3518918A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
HK1257853A1 (zh) 用於治療和預防放射性皮炎的組合物和方法
EP3423064A4 (en) TESTOSTERONE FORMULATIONS AND METHODS OF TREATMENT THEREFOR
IL272121A (en) Preparation and methods for the treatment of myopia
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
HK1259125A1 (zh) 治療和/或預防與血液相關病症的方法和製劑
EP3697387A4 (en) COMBINATION OF AS1411 AND SAPC-DOPS FOR THE TREATMENT OF MULTI-FORM GLIOBLASTOMA
EP3518951A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS
IL272147A (en) Methods and preparations for the treatment of cancer
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
SG11202004005RA (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
EP3131635A4 (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
EP3468540A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合